OBJECTIVES: Epithelial-mesenchymal transition (EMT) plays an important role in the progression, metastasis, and chemoresistance of pancreatic duct adenocarcinoma (PDAC); however, the expression of EMT markers and their clinical significance in PDAC patients who received neoadjuvant therapy (NAT) are unclear. METHODS: We examined the expression of EMT markers, including Zeb-1 (zinc finger E-box-binding homeobox 1), E-cadherin, and vimentin by immunohistochemistry in 120 PDAC patients who received NAT and pancreatectomy from 1999 to 2007. The results were correlated with clinicopathologic parameters and survival. RESULTS: Among 120 cases, 45 (37.5%) and 14 (11.7%) were positive for Zeb-1 and vimentin, respectively, and 25 (20.8%) were E-cadherin-low. The median overall survival and disease-free survival were 35.3 (standard deviation [SD], 2.8) and 15.9 (SD, 3.6) months, respectively, in vimentin-negative group compared with 16.1 (SD, 1.1) (P = 0.03) and 7.0 (SD, 1.1) months (P = 0.02) in the vimentin-positive group. In multivariate analysis, vimentin expression was an independent predictor of shorter disease-free survival (hazard ratio, 2.50; 95% confidence interval, 1.31-4.78; P = 0.016) and overall survival (hazard ratio, 2.55; 95% confidence interval, 1.33-4.89; P = 0.01). CONCLUSIONS: Epithelial-mesenchymal transition markers are frequently expressed in treated PDAC. Vimentin expression is a prognostic biomarker for survival in PDAC patients who received NAT.
OBJECTIVES: Epithelial-mesenchymal transition (EMT) plays an important role in the progression, metastasis, and chemoresistance of pancreatic duct adenocarcinoma (PDAC); however, the expression of EMT markers and their clinical significance in PDAC patients who received neoadjuvant therapy (NAT) are unclear. METHODS: We examined the expression of EMT markers, including Zeb-1 (zinc finger E-box-binding homeobox 1), E-cadherin, and vimentin by immunohistochemistry in 120 PDAC patients who received NAT and pancreatectomy from 1999 to 2007. The results were correlated with clinicopathologic parameters and survival. RESULTS: Among 120 cases, 45 (37.5%) and 14 (11.7%) were positive for Zeb-1 and vimentin, respectively, and 25 (20.8%) were E-cadherin-low. The median overall survival and disease-free survival were 35.3 (standard deviation [SD], 2.8) and 15.9 (SD, 3.6) months, respectively, in vimentin-negative group compared with 16.1 (SD, 1.1) (P = 0.03) and 7.0 (SD, 1.1) months (P = 0.02) in the vimentin-positive group. In multivariate analysis, vimentin expression was an independent predictor of shorter disease-free survival (hazard ratio, 2.50; 95% confidence interval, 1.31-4.78; P = 0.016) and overall survival (hazard ratio, 2.55; 95% confidence interval, 1.33-4.89; P = 0.01). CONCLUSIONS: Epithelial-mesenchymal transition markers are frequently expressed in treated PDAC. Vimentin expression is a prognostic biomarker for survival in PDAC patients who received NAT.
Authors: Matthew H G Katz; Huamin Wang; Aparna Balachandran; Priya Bhosale; Christopher H Crane; Xuemei Wang; Peter W T Pisters; Jeffrey E Lee; Jean-Nicolas Vauthey; Eddie K Abdalla; Robert Wolff; James Abbruzzese; Gauri Varadhachary; Xavier Chopin-Laly; Chusilp Charnsangavej; Jason B Fleming Journal: J Gastrointest Surg Date: 2011-11-08 Impact factor: 3.452
Authors: Malik Quasir Mahmood; Chris Ward; Hans Konrad Muller; Sukhwinder Singh Sohal; Eugene Haydn Walters Journal: Med Oncol Date: 2017-02-14 Impact factor: 3.064
Authors: J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg Journal: J Gastrointest Surg Date: 2001 Mar-Apr Impact factor: 3.452
Authors: Christopher R Shubert; John R Bergquist; Ryan T Groeschl; Elizabeth B Habermann; Patrick M Wilson; Mark J Truty; Rory L Smoot; Michael L Kendrick; David M Nagorney; Michael B Farnell Journal: Surgery Date: 2016-08-10 Impact factor: 3.982
Authors: Seung-Mo Hong; Ang Li; Kelly Olino; Christopher L Wolfgang; Joseph M Herman; Richard D Schulick; Christine Iacobuzio-Donahue; Ralph H Hruban; Michael Goggins Journal: Mod Pathol Date: 2011-05-06 Impact factor: 7.842
Authors: Julienne L Carstens; Sujuan Yang; Pedro Correa de Sampaio; Xiaofeng Zheng; Souptik Barua; Kathleen M McAndrews; Arvind Rao; Jared K Burks; Andrew D Rhim; Raghu Kalluri Journal: Cell Rep Date: 2021-04-13 Impact factor: 9.423
Authors: Damián Sánchez-Ramírez; Rafael Medrano-Guzmán; Fernando Candanedo-González; Jazmín De Anda-González; Luis Enrique García-Rios; Vadim Pérez-Koldenkova; Marcos Gutiérrez-de la Barrera; Sara Rodríguez-Enríquez; Marco Velasco-Velázquez; Silvia Cecilia Pacheco-Velázquez; Patricia Piña-Sánchez; Héctor Mayani; Alejandro Gómez-Delgado; Alberto Monroy-García; Ana Karen Martínez-Lara; Juan José Montesinos Journal: Eur J Histochem Date: 2022-02-17 Impact factor: 3.188